The brain as a central key organ.
Sometimes progress is hard to see, when looking at the big picture, because there is very little of it. But sometimes progress is hard to see because the big picture is out of focus. When perioperative deaths ascribed to anaesthesia are in the order of 1 in 20,000 operations and even changes in major morbidity require massive sample sizes to detect, neuroanaesthesia's most emphatic yardstick of progress is too crude to measure advances that have occurred over the most recent decade. We clearly need to become more familiar with neuropsychological tests that can detect subtle changes. Today, for elective neurosurgery, we are primarily in the business of doing two things--pushing the envelope for surgical intervention to include cases that would have been considered too risky 15 years ago, and reducing the frequency of "Uncle-Joe-has-never-been-the-same-since-they-operated-on-his-brain syndrome". Both of these areas of progress are empirically measurable, but we have not made much progress towards measuring them. Of course, this measurement problem plagues anaesthesiology generally, and we need to attend to it in general. Meanwhile, saying where we are relative to the recent past and the near future involves a lot of guesswork. What follows is my guess-work about progress in neurosurgical anaesthesiology.
Cottrell
J E
JE
Anesthesia Department, State University of New York-Health Science Center at Brooklyn 11203, USA.
D000758:Anesthesia / Q000009:adverse effects*; D000818:Animals; D017209:Apoptosis; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D002545:Brain Ischemia / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007036:Hypothermia, Induced; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D019635:Neurosurgical Procedures / Q000009:adverse effects*
D018696:Neuroprotective Agents